Target Name: MIR133B
NCBI ID: G442890
Review Report on MIR133B Target / Biomarker Content of Review Report on MIR133B Target / Biomarker
MIR133B
Other Name(s): Mir-133b | hsa-miR-133b | hsa-mir-133b | MicroRNA 133b | mir-133b | microRNA 133b | MIRN133B | miRNA133B

MIR133B: A Potential Drug Target and Biomarker

Mir133b, a non-coding RNA molecule, has been identified as a potential drug target and biomarker in various diseases, including cancer. Its unique structure and function have made it an attractive target for drug developers. In this article, we will explore the biology of Mir133b and its potential as a drug target and biomarker.

Mir133b: Structure and Function

Mir133b is a non-coding RNA molecule that was identified in the human genome in the non-coding RNA (ncRNA) family. It has a unique structure, with a 29 amino acid long cytoplasmic tail and a stem-loop region in the middle. The The cytoplasmic tail of Mir133b contains a conserved domain that is similar to those found in some reverse transcription factors (RTFs), which are proteins that play a crucial role in the process of RNA synthesis from DNA.

Mir133b functions as a negative regulator of gene expression in various tissues, including tissues with high levels of gene expression, such as the brain. It has been shown to regulate the expression of target genes by binding to their mRNAs and preventing their translation into proteins. This process is known as post-transcriptional regulation (PTR) and is a common mechanism used by various proteins to regulate gene expression.

Mir133b and Cancer

Cancer is a disease that has a high mortality rate and is a major public health issue. The development and progression of cancer are influenced by various factors, including genetic and epigenetic changes. Mir133b has been shown to be involved in the regulation of cancer cell growth and survival.

Studies have shown that Mir133b is downregulated in various types of cancer, including breast, ovarian, and prostate cancers. It has also been shown to be associated with cancer-related traits, such as poor prognosis and the development of metastasis.

Mir133b has also been shown to play a role in the regulation of cell signaling pathways that are involved in cancer progression. For example, it has been shown to regulate the signaling pathway associated with the oncogene Bcl-2, which is involved in the regulation of cell growth, survival, and angiogenesis.

Mir133b as a Drug Target

Mir133b has been identified as a potential drug target due to its unique structure and function. Its conserved domain and its ability to regulate gene expression make it an attractive target for small molecules.

One of the main advantages of Mir133b as a drug target is its promiscuity. Its conserved domain makes it easy to design small molecules that can interact with it and inhibit its function. This has led to the development of various compounds that have been shown to interact with Mir133b and have potential as anti-cancer drugs.

Another advantage of Mir133b as a drug target is its druggability. Its unique structure and function make it an attractive target for small molecules that can interact with it and inhibit its function. This has led to the development of various compounds that have been shown to interact with Mir133b and have potential as anti-cancer drugs.

Mir133b as a Biomarker

Mir133b has also been shown to be a potential biomarker for cancer. Its unique structure and function make it an attractive target for diagnostic tests that can detect its levels in cancer cells.

Studies have shown that Mir133b is downregulated in various types of cancer, including breast, ovarian, and prostate cancers. This suggests that its levels may be reduced in cancer cells, which could make it an attractive biomarker for cancer.

Mir133b has also been shown to be associated with

Protein Name: MicroRNA 133b

The "MIR133B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR133B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR134 | MIR1343 | MIR135A1 | MIR135A2 | MIR135B | MIR136 | MIR137 | MIR137HG | MIR138-1 | MIR138-2 | MIR139 | MIR140 | MIR141 | MIR142 | MIR143 | MIR144 | MIR145 | MIR1468 | MIR1469 | MIR146A | MIR146B | MIR1470 | MIR1471 | MIR147A | MIR147B | MIR148A | MIR148B | MIR149 | MIR150 | MIR151A | MIR151B | MIR152 | MIR153-1 | MIR153-2 | MIR1537 | MIR1538 | MIR1539 | MIR154 | MIR155 | MIR155HG | MIR1587 | MIR15A | MIR15B | MIR16-1 | MIR16-2 | MIR17 | MIR17HG | MIR181A1 | MIR181A1HG | MIR181A2 | MIR181A2HG | MIR181B1 | MIR181B2 | MIR181C | MIR181D | MIR182 | MIR1825 | MIR1827 | MIR183 | MIR184 | MIR185 | MIR186 | MIR187 | MIR188 | MIR18A | MIR18B | MIR1908 | MIR1909 | MIR190A | MIR190B | MIR191 | MIR1910 | MIR1911 | MIR1912 | MIR1913 | MIR1914 | MIR1915 | MIR1915HG | MIR192 | MIR193A | MIR193B | MIR193BHG | MIR194-1 | MIR194-2 | MIR194-2HG | MIR195 | MIR196A1 | MIR196A2 | MIR196B | MIR197 | MIR1972-1 | MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1